Allows flexibility to evaluate a range of formulation compositions in a single trial
Eliminates the "white space"—the extra time that can add up when moving between each stage of development
Improves decision-making, with real-time formulation decisions made based on emerging clinical data
Streamlines development by reducing time to the clinic and minimizing resource-intensive trial redesigns
Ideal for Modified Release Drug Products
A design space is a powerful tool to use in modified release drug development. Instead of assuming an in-vitro/in-vivo correlation, a design space allows critical-to-performance variables to be explored in one clinical study.
This can compress years of work, and multiple clinical trials into a single, efficient development cycle.
Alternative Strategies for Development of Modified Release Dosage Forms
Read MoreMeet our modified release and formulation design space experts
We help transform your molecules into the medicines of the future. Our partnership is focused on a single goal: Delivering new treatments to those in need. Fast.
Meet some of the team members you’ll collaborate with on your project.
Dr. Andrew Lewis
Chief Scientific Officer
Dr. Andrew (Andy) Lewis is the Chief Scientific Officer at Quotient Sciences. As the leader of Quotient Sciences' scientific teams...
About AndrewDr. Asma Patel
VP, Integrated Development Services
Dr. Asma Patel is responsible for providing scientific and technical support to Quotient Sciences' business development group and ...
About AsmaDr. Vanessa Zann
Vice President, Scientific Consulting, Translational Pharmaceutics & Clinical Pharmacology - USA
Dr. Vanessa Zann, Vice President, Scientific Consulting, Translational Pharmaceutics & Clinical Pharmacology - USA, has over t...
About VanessaJohn McDermott
Vice President, Scientific Consulting
John McDermott is Vice President of Scientific Consulting at Quotient Sciences. John leads Quotient Sciences' global drug developm...
About John